Abstract
Serenoa repens (SeR) is frequently associated with other natural compounds, such as lycopene (Ly), a carotenoid, and selenium (Se), an essential trace element, to increase its therapeutic activity in benign prostatic hyperplasia (BPH). The LY-Se-SeR association has a greater and stronger anti-inflammatory activity than SeR alone. In addition, the LY-Se-SeR combination is more effective than SeR alone in reducing prostate weight and hyperplasia, augmenting apoptosis, and reducing cell proliferation and growth factor expression. This experimental evidence suggests that Ly-Se-SeR association is superior to SeR alone in reducing benign prostate growth.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use*
-
Apoptosis / drug effects
-
Carotenoids / administration & dosage
-
Carotenoids / therapeutic use*
-
Cell Division / drug effects
-
Disease Models, Animal
-
Drug Evaluation, Preclinical
-
Drug Therapy, Combination
-
Epidermal Growth Factor / biosynthesis
-
Lycopene
-
Male
-
Organ Size / drug effects
-
Phytotherapy*
-
Plant Extracts / administration & dosage
-
Plant Extracts / therapeutic use*
-
Prostate / drug effects
-
Prostate / metabolism
-
Prostate / pathology
-
Prostatic Hyperplasia / drug therapy*
-
Random Allocation
-
Rats
-
Selenium / administration & dosage
-
Selenium / therapeutic use*
-
Serenoa*
-
Urinary Bladder Neck Obstruction / drug therapy
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Anti-Inflammatory Agents
-
Plant Extracts
-
Vascular Endothelial Growth Factor A
-
vascular endothelial growth factor A, rat
-
Carotenoids
-
Epidermal Growth Factor
-
Selenium
-
Lycopene